What is the appropriate management for a 17-year-old female with beta thalassemia presenting with microcytic anemia, as indicated by her CBC results?

Management of Beta Thalassemia in a 17-Year-Old Female

This patient with beta thalassemia requires monitoring only—no iron supplementation, no transfusions, and no chelation therapy at this time, as her hemoglobin of 10.1 g/dL with marked microcytosis (MCV 65) and normal RBC count (5.15) indicates thalassemia trait or mild thalassemia intermedia that is clinically asymptomatic. 1

Confirming the Diagnosis

The CBC pattern is pathognomonic for thalassemia rather than iron deficiency:

• The RDW of 16.6% with MCV 65 fL suggests thalassemia, as the combination of low MCV with RDW >14.0% can occur in both iron deficiency and thalassemia, but the elevated RBC count (5.15) strongly favors thalassemia over iron deficiency 2

• Hemoglobin electrophoresis is essential to characterize the specific beta thalassemia variant and quantify hemoglobin A2 and hemoglobin F levels, which will distinguish between beta thalassemia trait (elevated HbA2 typically >3.5%) and more severe forms 2, 1

• Check serum ferritin and transferrin saturation to confirm this is NOT iron deficiency anemia—ferritin should be normal or elevated (>30 μg/L), as iron deficiency would be inappropriate to treat in thalassemia and could lead to iron overload 2, 3

Treatment Algorithm Based on Severity

For Beta Thalassemia Trait (Most Likely in This Case)

• No treatment is required—patients are asymptomatic and require only monitoring 1

• Avoid iron supplementation unless true iron deficiency is documented with low ferritin (<30 μg/L), as inappropriate iron therapy leads to iron overload 2, 1

• Annual CBC monitoring to track hemoglobin stability 2

For Beta Thalassemia Intermedia (If Symptomatic)

• Transfusions are indicated only if the patient develops symptomatic anemia with exercise intolerance, growth failure, bone deformities from marrow expansion, or hemoglobin consistently <7 g/dL 1

• Hydroxyurea may be considered in patients with thalassemia intermedia to increase fetal hemoglobin production and reduce transfusion requirements 1

• Monitor for iron overload with serum ferritin every 3-6 months, as increased intestinal iron absorption occurs even without transfusions 1

For Beta Thalassemia Major (Unlikely Given This Presentation)

• Lifelong regular transfusions are required, typically starting before age 2 years, to maintain hemoglobin >9-10 g/dL 1

• Iron chelation therapy is mandatory once ferritin exceeds 1000 μg/L or after 10-20 transfusions to prevent cardiac, hepatic, and endocrine complications from iron deposition 1

• Hematopoietic stem cell transplantation is the only curative option and should be considered in young patients with HLA-matched donors 4, 1

Critical Monitoring Parameters

• Screen for complications of chronic hemolysis: cholelithiasis (gallstones), splenomegaly, leg ulcers, and pulmonary hypertension 1, 5

• Assess for bone marrow expansion effects: frontal bossing, maxillary hyperplasia, pathologic fractures 1

• Monitor endocrine function annually: thyroid, parathyroid, glucose metabolism, and growth parameters, as iron deposition affects these organs even in non-transfused patients 1

• Cardiac evaluation with echocardiography and ECG if ferritin >1000 μg/L or if receiving transfusions 1

Common Pitfalls to Avoid

Do not prescribe iron supplementation based solely on microcytic anemia—this is the most critical error, as thalassemia patients have normal or increased iron stores, and supplementation causes toxic iron accumulation 2, 1

Do not assume all microcytic anemia is iron deficiency—the elevated RBC count (5.15) with severe microcytosis (MCV 65) and only mild anemia (Hb 10.1) is the opposite pattern of iron deficiency, which typically shows low RBC count with more severe anemia relative to the MCV 2, 3

Do not start transfusions prematurely—transfusion dependence commits the patient to lifelong therapy with iron chelation and should be reserved for symptomatic anemia or hemoglobin consistently <7 g/dL 1

Genetic Counseling

• Provide genetic counseling regarding autosomal recessive inheritance pattern and 25% risk of thalassemia major in offspring if partner is also a carrier 1

• Screen family members, particularly siblings, as they have a 25% chance of being affected and 50% chance of being carriers 1

• Partner screening is essential before pregnancy planning, with hemoglobin electrophoresis recommended for partners from high-risk ethnic backgrounds (Mediterranean, Middle Eastern, Asian, African descent) 1